

Sign up to "Stay on Track With SOMAVERT" by visiting SOMAVERT.com to receive resources to help you better understand and track your treatment journey.

INDICATION

SOMAVERT is a prescription medicine for acromegaly. It is for patients whose disease has not been controlled by surgery or radiation, or patients for whom these options are not appropriate. The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood.

SELECTED SAFETY INFORMATION

Do not use SOMAVERT® (pegvisomant for injection) if you are allergic to SOMAVERT or anything that is in it.

Be sure to tell your doctor if you use narcotic painkillers (opioid medicines) because the dose of SOMAVERT may need to be changed.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

about how you are feeling." -Kenneth

MOVE FORWARD with SOMAVERT: YOUR GUIDE TO STAYING PREPARED

You know better than anyone else what it's like to live with acromegaly. Sharing what you're going through with your doctor, and asking the right questions, can help you get the most out of your treatment journey.

Monitoring My Acromegaly

Patient Resources

Learn More

Actual acromegaly patient


IMPORTANT SAFETY INFORMATION

PRESCRIBING **INFORMATION**

DOWNLOAD **PRINTABLE PDF**



"When you go into your appointments, make sure you talk with your doctor



START



Questions you may consider asking your doctor

Why is it important to **measure and control your IGF-I level** while taking SOMAVERT?

How can you keep track of any acromegaly signs and symptoms you may experience?

What side effects are possible with SOMAVERT?

Topics to consider discussing with your doctor

- The status of your IGF-I level, and if your SOMAVERT dose needs adjustment
- The effect that symptoms are having on your daily life
- Laboratory test results you may need
- Any other comments or questions you may have.

Please see the *Learn More* section for a list of resources designed to help you better understand and track your treatment journey.

SELECTED SAFETY INFORMATION

Blood sugar levels may go down when taking SOMAVERT. Be sure to tell your doctor if you use insulin or other medicines (oral hypoglycemic medicines) for diabetes. The dose of these medicines may need to be reduced when you use SOMAVERT. Some people who have used SOMAVERT have developed liver problems. These problems generally disappeared when those people stopped taking SOMAVERT.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.


HOME

Reminders for you

SOMAVERT was shown to help patients with acromegaly lower IGF-I levels.

Acromegaly signs and symptoms can include:





Your doctor may track your IGF-I levels to determine whether SOMAVERT is working or if your dose needs adjusting.

The most common side effects with SOMAVERT are infection, pain, nausea, diarrhea, abnormal liver function tests, flu-like symptoms, and reaction at the injection site. These are not all of the possible side effects of SOMAVERT. For more information, speak to your doctor.

IGF-I, insulin-like growth factor I.





DOSING AND INJECTING



Questions you may consider asking your doctor

How should you store and handle SOMAVERT? Is there a benefit to receiving the 30-day package compared to the one-day package? **What dose** of SOMAVERT is right for you? How and in which areas should you inject SOMAVERT? What is the best way for you to track your injection? How do you request one-on-one virtual or in-home injection training with a nurse?

Topics to consider discussing with your doctor

Ple	ease see the Learn More section for a list of
	Any other comments or questions you may h
	What dosage of SOMAVERT is right for you
	How often and where you should inject SOM
	An effective routine for you to inject SOMAV

SELECTED SAFETY INFORMATION

Stop the drug right away and call your doctor if you get any of these symptoms:

- Your skin or the white part of your eyes turns yellow (jaundice)
- Your urine turns dark
- Your bowel movements (stools) turn light in color

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

MONITORING MY ACROMEGALY

'ERT

IAVERT

have

resources designed to help you better understand and track your treatment journey.

- You do not feel like eating for several days
- You feel sick to your stomach (nausea)

Dosing Information

SOMAVERT is available in 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg with the prefilled diluent syringe. The different dosage options help your healthcare provider determine the best treatment dose for you.

Initially you will receive a dose of 40 mg of SOMAVERT from your healthcare provider. As you begin taking SOMAVERT, your healthcare provider may adjust the dose to find what is most effective for managing your IGF-I levels.

Storage and Packaging

With flexible packaging options, SOMAVERT is available in a one-day package or a 30-day package designed to save space.

SOMAVERT can be stored at room temperature up to 77°F (25°C) for a single period of up to 30 days. Refrigerator storage is recommended for longer-term storage prior to reconstitution. Do not freeze SOMAVERT.

IMPORTANT SAFETY INFORMATION

PRESCRIBING INFORMATION

DOWNLOAD **PRINTABLE PDF**

Reminders for you



You must use the mixed SOMAVERT immediately after you mix it.

- You have unexplained tiredness
- You have pain in the stomach area (abdomen)

PATIENT RESOURCES



Questions you may consider asking your doctor

How can the Pfizer Bridge Program[®]* help you with questions you have about your insurance?

Does your plan require reauthorization to continue your SOMAVERT treatment? What is the process for getting reauthorized?

What do you need to do in the event of a change in insurance coverage?

Topics to consider discussing with your doctor

The patient support provided by the Pfizer Bridge Program

How to handle prescription reauthorization, if it applies to you

Any other comments or questions you may have

Please see the *Learn More* section for a list of resources designed to help you better understand and track your treatment journey.

*Certain programs and services powered by Pfizer RxPathways[®].

DOSING AND INJECTING





Financial support is available for eligible SOMAVERT patients. For more information about this program and other patient support offerings, please call the **Pfizer Bridge Program** at 1-800-645-1280 or visit SOMAVERT.com to learn more.

IMPORTANT SAFETY INFORMATION

PRESCRIBING INFORMATION

DOWNLOAD **PRINTABLE PDF**

Reminders for you



Pfizer Bridge Program







Discussion checklist

Monitoring my acromegaly	Patient resources
The status of your IGF-I level, and if your SOMAVERT	The patient support p
dose needs adjustment	How to handle presc
The effect that symptoms are having on your daily life	Any other comments
Laboratory test results you may need	
Any other comments or questions you may have	
Dosing and injecting	Notes
Dosing and injecting An effective routine for you to inject SOMAVERT	Notes
	Notes
An effective routine for you to inject SOMAVERT	Notes

SELECTED SAFETY INFORMATION

If you have stopped SOMAVERT because of an allergic reaction, your doctor will carefully monitor what happens if you start SOMAVERT again. The most common side effects with SOMAVERT are infection, pain, nausea, diarrhea, abnormal liver function tests, flu-like symptoms, and reaction at the injection site. These are not all of the possible side effects of SOMAVERT. For more information, speak to your doctor.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

PATIENT RESOURCES


provided by the **Pfizer Bridge Program**

ription reauthorization, if it applies to you

or questions you may have _____

LEARN MORE





To hear patient stories, be sure to like us at **Facebook.com/PfizerSomavert**


SELECTED SAFETY INFORMATION

Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness. SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother's milk or if it can harm the baby.

<u>1-800-FDA-1088</u>.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

DISCUSSION CHECKLIST





You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <u>www.fda.gov/MedWatch</u> or call

IMPORTANT SAFETY INFORMATION



DOWNLOAD **PRINTABLE PDF** **Getting Started on SOMAVERT** Patient Insurance Roadmap

Pfizer Bridge Program

GETTING STARTED ON SOMAVERT





For downloadable resources and to sign up for more information, visit us at <u>SOMAVERT.com</u>. To hear patient stories, be sure to like us at <u>Facebook.com/PfizerSomavert</u>

SELECTED SAFETY INFORMATION

Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness. SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother's milk or if it can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <u>www.fda.gov/MedWatch</u> or call <u>1-800-FDA-1088</u>.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

DISCUSSION CHECKLIST The Getting Started on SOMAVERT Folder contains helpful information, including a patient brochure, instructions and tips for injecting SOMAVERT, and details on how to keep track of your symptoms.

IMPORTANT SAFETY INFORMATION



DOWNLOAD PRINTABLE PDF

Getting Started on SOMAVERT

Patient Insurance Roadmap

Pfizer Bridge Program

PATIENT INSURANCE ROADMAP





For downloadable resources and to sign up for more information, visit us at **SOMAVERT.com**. To hear patient stories, be sure to like us at **Facebook.com/PfizerSomavert**

SELECTED SAFETY INFORMATION

Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness. SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother's milk or if it can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <u>www.fda.gov/MedWatch</u> or call <u>1-800-FDA-1088</u>.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

DISCUSSION CHECKLIST

The Patient Insurance Roadmap

is a brochure that offers tips and pointers to help guide you through the insurance process.

IMPORTANT SAFETY INFORMATION



DOWNLOAD **PRINTABLE PDF**



Getting Started on SOMAVERT

Patient Insurance Roadmap

Pfizer Bridge Program

PFIZER BRIDGE PROGRAM







For downloadable resources and to sign up for more information, visit us at <u>SOMAVERT.com</u>. To hear patient stories, be sure to like us at <u>Facebook.com/PfizerSomavert</u>

SELECTED SAFETY INFORMATION

Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness. SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother's milk or if it can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <u>www.fda.gov/MedWatch</u> or call <u>1-800-FDA-1088</u>.

Please see full Important Safety Information and full Prescribing Information, including Patient Information, via menu below.

DISCUSSION CHECKLIST

The Pfizer Bridge Program—

For more information about patient support offerings, call <u>1-800-645-1280</u> from 9 AM to 7 PM Eastern Time, Monday through Friday.







Getting Started on SOMAVERT

Patient Insurance Roadmap

Pfizer Bridge Program

IMPORTANT SAFETY INFORMATION





INDICATION

SOMAVERT is a prescription medicine for acromegaly. It is for patients whose disease has not been controlled by surgery or radiation, or patients for whom these options are not appropriate. The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood.

IMPORTANT SAFETY INFORMATION

Do not use SOMAVERT[®] (pegvisomant for injection) if you are allergic to SOMAVERT or anything that is in it. Be sure to tell your doctor if you use narcotic painkillers (opioid medicines) because the dose of SOMAVERT may need to be changed. Blood sugar levels may go down when taking SOMAVERT. Be sure to tell your doctor if you use insulin or other medicines (oral hypoglycemic medicines) for diabetes. The dose of these medicines may need to be reduced when you use SOMAVERT. Some people who have used SOMAVERT have developed liver problems. These problems generally disappeared when those people stopped taking SOMAVERT.

Stop the drug right away and call your doctor if you get any of these symptoms: • Your skin or the white part of your eyes turns yellow (jaundice)

- Your urine turns dark
- Your bowel movements (stools) turn light in color
- You do not feel like eating for several days
- You feel sick to your stomach (nausea)
- You have unexplained tiredness

• You have pain in the stomach area (abdomen) Your doctor may do blood tests before and during your treatment with SOMAVERT to check that the IGF-I levels in your blood are normal and/or that your liver is working correctly. Your dose of SOMAVERT may be changed based on the results of these tests. If you have stopped SOMAVERT because of an allergic reaction, your doctor will carefully monitor what happens if you start SOMAVERT again. The most common side effects with SOMAVERT are infection, pain, nausea, diarrhea, abnormal liver function tests, flu-like symptoms, and reaction at the injection site. These are not all of the possible side effects of SOMAVERT. For more information, speak to your doctor. Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness. SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother's milk or if it can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. Please see full Prescribing Information via menu below.

PP-SOM-USA-0909



All rights reserved.







September 2021



PRESCRIBING INFORMATION



Initial U.S. Approval: 2003

--RECENT MAJOR CHANGES----Dosage and Administration (2.3, 2.4) 8/2021

SOMAVERT is a growth hormone receptor antagonist indicated for the treatment of --ADVERSE REACTIONS----acromegaly in patients who have had an inadequate response to surgery or radiation Most common reported adverse reactions (>6%) are infection, pain, nausea, diarrhea, therapy, or for whom these therapies are not appropriate. The goal of treatment is to abnormal liver tests, flu syndrome, injection site reaction. (6) normalize serum insulin-like growth factor-I (IGF-I) levels. (1)

- Follow reconstitution and injection procedures. (2.3, 2.4)

-----DOSAGE FORMS AND STRENGTHS----For injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg lyophilized powder in a single-dose vial for reconstitution supplied with a prefilled syringe containing 1 mL of diluent (Sterile Water for Injection, USP). (3)

FUL	L PRES	CRIBING I
1	INDIC	ATIONS AN
2	DOSA	GE AND AD
	2.1	Dosage li
	2.2	Assess Liv
	2.3	Loading [
	2.4	Maintenar
3	DOSA	GE FORMS
4		RAINDICAT
5		INGS AND
	5.1	Hypoglyce
	5.2	Liver Toxic
	5.3	Cross-Re
	5.4	Lipohype
	5.5	Systemic
6	ADVEF	RSE REACT
	6.1	Clinical T
	6.2	Immunog
	6.3	Postmark
7	DRUG	INTERACT
	7.1	Insulin ar
	7.2	Opioids

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Information benefit from increased SOMAVERT dosage.

- are elevated.
- are below the normal range.

IMPORTANT SAFETY INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SOMAVERT safely and effectively. See full prescribing information for SOMAVERT.

SOMAVERT (pegvisomant) for injection, for subcutaneous use

--INDICATIONS AND USAGE--

--DOSAGE AND ADMINISTRATION-

 Administer a 40 mg loading dose subcutaneously under physician supervision. (2.1) • After proper injection instruction, on day after loading dose, patients or caregivers begin daily subcutaneous injections of 10 mg. (2.1)

• Adjust dosage in 5 mg increments or decrements until serum IGF-I concentrations are maintained within age-adjusted normal range. Do not adjust dosage based on growth hormone (GH) levels or signs or symptoms of acromegaly. (2.1)

• Dosage range is 10 mg to 30 mg once daily. (2.1)

• Perform liver tests prior to first dosage and if greater than 3 times upper limit of normal should work-up prior to SOMAVERT administration. (2.2)

FULL PRESCRIBING INFORMATION: CONTENTS*

ND USAGE

DMINISTRATION

nformation

iver Tests Prior to Initiation of SOMAVERT

Dose Injection Procedure

Ince Dose Injection Procedure

AND STRENGTHS

FIONS

PRECAUTIONS

cemia Associated With GH Lowering in Patients With Diabetes Mellitus icity

eactivity With GH Assays

rtrophy : Hypersensitivity

FIONS

Trials Experience

genicity

keting Experience

FIONS

and/or Oral Hypoglycemic Agents

The recommended loading dose of SOMAVERT is 40 mg given subcutaneously, under healthcare provider supervision. Provide proper training in subcutaneous injection technique to patients or their caregivers so they can receive once daily subcutaneous injections. On the next day following the loading dose, instruct patients or their caregivers to begin daily subcutaneous injections of 10 mg of SOMAVERT.

Titrate the dosage to normalize serum IGF-I concentrations (serum IGF-I concentrations should be measured every four to six weeks). The dosage should not be based on growth hormone (GH) concentrations or signs and symptoms of acromegaly. It is unknown whether patients who remain symptomatic while achieving normalized IGF-I concentrations would

• Increase the dosage by 5 mg increments every 4-6 weeks if IGF-I concentrations

• Decrease the dosage by 5 mg decrements every 4-6 weeks if IGF-I concentrations

None. (4)

---WARNINGS AND PRECAUTIONS------

- *Hypoglycemia*: Monitor blood glucose in patients with diabetes mellitus and reduce anti-diabetic drug therapy as necessary. (5.1)
- Liver Toxicity: Should have more frequent liver tests and/or discontinue SOMAVERT. (5.2)
- *Systemic Hypersensitivity*: Monitor closely when re-initiating SOMAVERT in patients with systemic hypersensitivity. (5.5)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

--CONTRAINDICATIONS---

---DRUG INTERACTIONS-

- *Insulin and/or Oral hypoglycemic Agents:* Patients with acromegaly and with diabetes mellitus may require careful monitoring and dose reductions of insulin and/or oral hypoglycemic agents. (5.2, 7.1)
- *Opioids:* Patients on opioids may need higher SOMAVERT doses to achieve appropriate IGF-I suppression. (7.2)

----USE IN SPECIFIC POPULATIONS------Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. (8.3)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 10 OVERDOSAGE
- **11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY
 - 12.1 Mechanism of Action
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- **14 CLINICAL STUDIES**
- **16 HOW SUPPLIED/STORAGE AND HANDLING**
- **17 PATIENT COUNSELING INFORMATION**

*Sections or subsections omitted from the full prescribing information are not listed.

• IGF-I levels should also be monitored when a SOMAVERT dose given in multiple injections is converted to a single daily injection [see Clinical Pharmacology (12)]. The recommended dosage range is between 10 mg to 30 mg given subcutaneously once daily and the maximum daily dosage is 30 mg given subcutaneously once daily.

2.2 Assess Liver Tests Prior to Initiation of SOMAVERT

Prior to the start of SOMAVERT, patients should have an assessment of baseline levels of liver tests [serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP)]. For recommendations regarding initiation of SOMAVERT based on baseline liver tests and recommendations for monitoring of liver tests while on SOMAVERT, refer to Table 1 in *Warning and Precautions (5.2)*.

2.3 Loading Dose Injection Procedure

The following instructions are for the **healthcare provider** to reconstitute and prepare the 40 mg loading dose. The healthcare provider will need to reconstitute 2 vials of lyophilized powder of SOMAVERT each containing 20 mg of pegvisomant with supplied diluent [two vials of lyophilized powder and two syringes containing 1 mL of diluent (Sterile Water for Injection, USP) will be needed for the 40 mg loading dose]. The healthcare provider will also need to inject the reconstituted SOMAVERT solution twice into the patient's upper arm, upper thigh, abdomen, or buttocks (each injection in a different area).

(a) Before administering the loading dose, remove 1 vial of lyophilized powder of SOMAVERT containing 20 mg of pegvisomant and one syringe containing 1 mL of diluent from the refrigerator, if refrigerated, about 10 minutes prior to the planned injection time.



PRESCRIBING INFORMATION

12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY

DOWNLOAD **PRINTABLE PDF**

Discussion Checklist

Revised: 8/2021





- angle.
- 2.4 Maintenance Dose Injection Procedure
- - to inject.
 - of solution.

3 DOSAGE FORMS AND STRENGTHS For injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg white lyophilized powder in a singledose vial for reconstitution supplied with a prefilled syringe containing 1 mL of diluent (Sterile Water for Injection, USP).

4 CONTRAINDICATIONS None.

5 WARNINGS AND PRECAUTIONS

5.1 Hypoglycemia Associated With GH Lowering in Patients With Diabetes Mellitus GH opposes the effects of insulin on carbohydrate metabolism by decreasing insulin sensitivity; thus, glucose tolerance may improve in some patients treated with SOMAVERT Patients should be carefully monitored and doses of anti-diabetic drugs reduced as necessary to avoid hypoglycemia in patients with diabetes mellitus.

5.2 Liver Toxicity hepatic laboratory abnormalities.

PRESCRIBING **INFORMATION PAGE 1**

Reconstitute the first 20 mg vial of lyophilized powder of SOMAVERT containing 20 mg of pegvisomant with diluent. When using the diluent in the syringe, inject the contents of the syringe slowly onto the sides of the vial containing lyophilized powder of SOMAVERT. Do not inject the diluent directly on the powder.

(c) Do not invert the vial or shake the solution as this may cause denaturation of the pegvisomant protein. Slowly swirl the solution to ensure that all of the lyophilized powder has gone into solution. If foaming of the reconstituted SOMAVERT solution is seen, the solution is likely damaged and therefore inappropriate to inject.

(d) Visually inspect the reconstituted SOMAVERT solution for particulate matter and discoloration prior to administration. The reconstituted solution should be clear. If the solution is cloudy, do not use it. Once reconstituted, the solution will contain 20 mg of pegvisomant in 1 mL of solution.

Withdraw the 1 mL reconstituted SOMAVERT solution. The solution must be administered immediately after reconstitution.

(f) Inject the first reconstituted SOMAVERT solution (20 mg/mL) subcutaneously into the patient's upper arm, upper thigh, abdomen, or buttocks using a 90-degree

(g) Repeat steps (a) to (e) to reconstitute the second SOMAVERT dose of 20 mg.

(h) Finally, inject the second reconstituted SOMAVERT solution (20 mg/mL) subcutaneously into the patient's upper arm, upper thigh, abdomen, or buttocks using a 90-degree angle (different area than the first injection).

For patient or caregiver instructions for reconstitution and administration of daily doses (10 mg to 30 mg), see the Patient's Instructions for Use.

a) Before administering the dose, remove 1 vial of lyophilized powder of SOMAVERT containing 10 mg, 15 mg, 20 mg, 25 mg or 30 mg of pegvisomant and one syringe containing 1 mL of diluent from the refrigerator, if refrigerated about 10 minutes prior to the planned injection time.

b) Reconstitute the lyophilized powder of SOMAVERT with diluent. When using the diluent in the 2.25 mL syringe, inject the contents of the syringe slowly onto the sides of the vial containing lyophilized powder of SOMAVERT. Do not inject the diluent directly on the powder.

c) Do not invert the vial or shake the solution as this may cause denaturation of the peqvisomant protein. Slowly swirl the solution to ensure that all of the lyophilized powder has gone into solution. If foaming of the reconstituted SOMAVERT solution is seen, the solution is likely damaged and therefore inappropriate

d) Visually inspect the reconstituted SOMAVERT solution for particulate matter and discoloration prior to administration. The reconstituted solution should be clear. If the solution is cloudy, do not use it. Once reconstituted, the solution will contain 10 mg, 15 mg, 20 mg, 25 mg or 30 mg of pegvisomant in 1 mL

e) Withdraw the 1 mL reconstituted SOMAVERT solution. The solution must be administered immediately after reconstitution.

f) Inject the reconstituted SOMAVERT solution subcutaneously into the upper arm upper thigh, abdomen, or buttocks using a 90-degree angle.

Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with SOMAVERT. Table 1 lists recommendations regarding initiation of treatment with SOMAVERT, based on the results of these liver tests (LTs).

Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in < 2% of subjects among two open-label trials (with a total of 147 patients) These reports were not associated with an increase in bilirubin. Transaminase elevations normalized with time, most often after suspending treatment. Postmarketing reports have identified elevations in serum hepatic transaminases up to greater than 20 times ULN associated with elevation in total bilirubin greater than 2 times ULN. In many of these cases, discontinuation of SOMAVERT therapy resulted in improvement or resolution of

SOMAVERT should be used in accordance with the information presented in Table 2 with respect to liver test abnormalities while on SOMAVERT treatment

Table 1. Recommendations of Initiating SOMAVERT Based on Baseline LTs and Periodic Monitoring of LTs During SOMAVERT Treatment

Baseline LT Levels	Recommendations
Normal	 May treat with SOMAVERT. Monitor LTs at monthly intervals during the treatment, quarterly for the next 6 months for the next year.
Elevated, but less than or equal to 3 times ULN	May treat with SOMAVERT; however, monito at least one year after initiation of therapy an the next year.
Greater than 3 times ULN	 Do not treat with SOMAVERT until a compestablishes the cause of the patient's liver Determine if cholelithiasis or choledocholic particularly in patients with a history of prosomatostatin analogs. Based on the workup, consider initiation of SOMAVERT. If the decision is to treat, LTs and clinical subseminitored very closely.

If a patient develops LT elevations, or any other signs or symptoms of liver dysfunction while receiving SOMAVERT, the following patient management is recommended (Table 2).

Table 2. Clinical Recommendations Based on Liver Test Results While on SOMAVERT

LT Levels and Clinical Signs/Symptoms	Recom	
Greater than or equal to 3 but less than 5 times ULN (without signs/symptoms of hepatitis or other liver injury, or increase in serum TBIL)	 May continue the However, monito determine if furth (see below). Perform a compr to discern if an a dysfunction is pr 	
At least 5 times ULN, or transaminase elevations at least 3 times ULN associated with any increase in serum TBIL (with or without signs/symptoms of hepatitis or other liver injury)	 Discontinue SOM Perform a compression workup, including if and when serut normal. If LTs normalize (alternative cause is discovered), corre-initiation of the with frequent LT 	
Signs or symptoms suggestive of hepatitis or other liver injury (e.g., jaundice, bilirubinuria, fatigue, nausea, vomiting, right upper quadrant pain, ascites, unexplained edema, easy bruisability)	 Immediately perf hepatic workup. If liver injury is c should be discon 	

5.3 Cross-Reactivity With GH Assays

SOMAVERT has significant structural similarity to growth hormone (GH) which causes it to cross-react in commercially available GH assays. Since serum concentrations of therapeutically effective doses of SOMAVERT are generally 100 to 1000 times higher than the actual serum GH concentrations seen in patients with acromegaly, measurements of serum GH concentrations will appear falsely elevated.

5.4 Lipohypertrophy

There have been cases of lipohypertrophy in patients treated with SOMAVERT. In a doubleblind, 12-week, placebo-controlled study, there was one case (1.3%) of injection site lipohypertrophy reported in a subject receiving 10 mg/day. The subject recovered while on treatment. Among two open-label trials (with a total of 147 patients), there were two subjects, both receiving 10 mg/day, who developed lipohypertrophy. One case recovered while on treatment, and one case resulted in a discontinuation of treatment. Injection sites should be rotated daily to help prevent lipohypertrophy (different area than the last injection).

5.5 Systemic Hypersensitivity

In patients with systemic hypersensitivity reactions, caution and close monitoring should be exercised when re-initiating SOMAVERT therapy [see Adverse Reactions (6.3)].

6 ADVERSE REACTIONS

PRESCRIBING

INFORMATION

Clinically significant adverse reactions that appear in other section of the labeling include: • Hypoglycemia Associated with GH Lowering in Patients with Diabetes Mellitus *[see*] Warnings and Precautions (5.1)]

- Liver Toxicity [see Warnings and Precautions (5.2)]
- Cross-Reactivity with GH Assays [see Warnings and Precautions (5.3)]
- Lipohypertrophy [see Warnings and Precautions (5.4)]

DOWNLOAD

PRINTABLE PDF

• Systemic Hypersensitivity [see Warnings and Precautions (5.5)] Elevations of serum concentrations of ALT and AST greater than ten times the ULN were reported in two patients (0.8%) exposed to SOMAVERT in pre-approval clinical studies. One patient was rechallenged with SOMAVERT, and the recurrence of elevated transaminase levels suggested a probable causal relationship between administration of the drug and the

IMPORTANT SAFETY INFORMATION

Discussion Checklist

Learn More

ng the first 6 months of nths and then bi-annually

onitor LTs monthly for py and then bi-annually for

omprehensive workup liver dysfunction. cholithiasis is present of prior therapy with

ion of therapy with

ical symptoms should

nmendations

erapy with SOMAVERT or LTs weekly to her increases occur

prehensive hepatic workup alternative cause of liver resent

MAVERT immediately prehensive hepatic ng serial LTs, to determine um levels return to

(regardless of whether an e of the liver dysfunction consider cautious nerapy with SOMAVERT, monitoring.

form a comprehensive

confirmed, the drug ntinued.





genetic predictors.

6.1 Clinical Trials Experience placebo-controlled study.

Table 3. Adverse Reactions in a 12-week Placebo-Controlled Study in Patients with Acromegaly³

	Dissaha		SOMAVERT	
	Placebo n=32	10 mg/day n=26	15 mg/day n=26	20 mg/day N=28
Infection [†]	2 (6%)	6 (23%)	0	0
Pain	2 (6%)	2 (8%)	1 (4%)	4 (14%)
Nausea	1 (3%)	0	2 (8%)	4 (14%)
Diarrhea	1 (3%)	1 (4%)	0	4 (14%)
Abnormal liver function tests	1 (3%)	3 (12%)	1 (4%)	1 (4%)
Flu syndrome	0	1 (4%)	3 (12%)	2 (7%)
Injection site reaction	0	2 (8%)	1 (4%)	3 (11%)
Dizziness	2 (6%)	2 (8%)	1 (4%)	1 (4%)
Accidental injury	1 (3%)	2 (8%)	1 (4%)	0
Back pain	1 (3%)	2 (8%)	0	1 (4%)
Sinusitis	1 (3%)	2 (8%)	0	1 (4%)
Chest pain	0	1 (4%)	2 (8%)	0
Peripheral edema	0	2 (8%)	0	1 (4%)
Hypertension	0	0	2 (8%)	0
Paresthesia	2 (6%)	0	0	2 (7%)

patients treated with SOMAVERT than in patients treated with placebo. [†] The 6 events coded as "infection" in the group treated with SOMAVERT 10 mg were reported as cold symptoms (3), upper respiratory infection (1), blister (1), and ear infection (1). The 2 events in the placebo group were reported as cold symptoms (1) and chest infection (1).

6.2 Immunogenicity

6.3 Postmarketing Experience causal relationship to drug exposure.

PRESCRIBING **INFORMATION PAGE 2**

elevation in liver enzymes. A liver biopsy performed on the second patient was consistent with chronic hepatitis of unknown etiology. In both patients, the transaminase elevations normalized after discontinuation of the drug.

Elevations in ALT and AST levels were not associated with increased levels of TBIL and ALP, with the exception of two patients with minimal associated increases in ALP levels (i.e., less than 3 times ULN). The transaminase elevations did not appear to be related to the dose of SOMAVERT administered, generally occurred within 4 to 12 weeks of initiation of therapy, and were not associated with any identifiable biochemical, phenotypic, or

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 12-week randomized, placebo-controlled, double-blind, fixed-dose study of SOMAVERT in subjects with acromegaly, 32 subjects received placebo and 80 subjects received SOMAVERT once daily [see Clinical Studies (14)]. A total of 108 subjects (30 placebo, 78 SOMAVERT) completed 12 weeks of study treatment.

Overall, eight patients with acromegaly (5.3%) withdrew from pre-marketing clinical studies because of adverse events, including two patients with marked transaminase elevations, one patient with lipohypertrophy at the injection sites, and one patient with substantial weight gain. Most adverse events did not appear to be dose-dependent Table 3 shows the incidence of adverse events that were reported in at least two patients treated with SOMAVERT and at frequencies greater than placebo during the 12-week,

In pre-marketing clinical studies, approximately 17% of the SOMAVERT-treated patients developed low titer, non-neutralizing anti-GH antibodies. Although the presence of these antibodies did not appear to impact the efficacy of SOMAVERT, the long-term clinical significance of these antibodies is not known. No assay for anti-pegvisomant antibodies is commercially available for patients receiving SOMAVERT.

The data above reflect the percentage of patients whose test results were considered positive for antibodies to SOMAVERT. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SOMAVERT with the incidence of antibodies to other products may be misleading.

The following adverse reactions have been identified during post-approval use of SOMAVERT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a

Systemic hypersensitivity reactions including anaphylactic reactions, laryngospasm angioedema, generalized skin reactions (rash, erythema, pruritus, urticaria) have been reported in post-marketing use. Some patients required hospitalization. Symptoms did not re-occur in all patients after re-challenge [see Warnings and Precautions (5.5)].

without treatment during pregnancy, particularly if acromegaly is treated before pregnancy. Animal Data both studies.

<u>Registry of Patients With Acromegaly Treated With SOMAVERT</u> ACROSTUDY is an international observational registry that captures long term safety data in patients with acromegaly treated with SOMAVERT, as used in clinical practice. Treatment dose and schedule were at the discretion of each treating physician. Although safety monitoring as per the recommended schedule was mandatory, not all assessments were performed at all time points for every patient. Because of this, comparison of rates of adverse events to those in the original clinical trial is not appropriate. In an interim report, there were 1288 patients enrolled (mean duration of treatment 3.7 years). At the start of SOMAVERT treatment 648 patients were on SOMAVERT monotherapy for acromegaly. Of the 454 patients who had a normal AST and ALT at baseline, 4 patients had elevated tests >3 times ULN, two of whom had elevated tests >5 times ULN. Lipohypertrophy was reported in 6 (0.5%) patients. MRIs were compared to any previous ones, and a change in tumor volume was reported as significant locally only if the diameter increased by more than 3 mm for microadenomas or volume increased by more than 20% for macroadenomas. All MRI changes considered significant at the local reading were reanalyzed centrally. Of the 747 patients who had a MRI reported at baseline and at least once during follow up in the study, 51 (7%) were reported to have an increase by local MRI. Of these, 16 patients (2%) had confirmation of this increase, 6 patients had a decrease, 12 had "no change"; there was 1 with insufficient data and 16 patients did not have a central MRI reading. 7 DRUG INTERACTIONS 7.1 Insulin and/or Oral Hypoglycemic Agents After initiation of SOMAVERT, patients with acromegaly and diabetes mellitus treated with insulin and/or oral hypoglycemic agents may require dose reductions of insulin and/or oral hypoglycemic agents [see Warnings and Precautions (5.1)]. 7.2 Opioids In clinical studies, patients taking opioids often needed higher SOMAVERT doses to normalize IGF-I concentrations compared with patients not receiving opioids. The mechanism of this interaction is not known. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy <u>Risk Summary</u> Postmarketing reports of SOMAVERT use in pregnant women are insufficient to establish a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. Acromegaly may improve during pregnancy *(see Clinical Considerations)*. In animal reproduction studies, fetotoxicity was observed at a dose that was 6 times the maximum recommended human dose based on body surface area following subcutaneous administration of pegvisomant during organogenesis or during the preimplantation period (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. **Clinical Considerations** Disease-associated maternal and/or embryofetal risk Published data from case reports, case series, and a small interventional study in pregnant women with acromegaly have demonstrated that acromegaly may improve or stabilize In rare cases, acromegaly may worsen during pregnancy. Since IGF-1 levels may change physiologically during pregnancy and interpreting IGF-1 and growth hormone levels in pregnant women with acromegaly may be unreliable, clinical monitoring is recommended. The effects of pegvisomant on early embryonic development and embryo-fetal development were evaluated in two separate studies, which were conducted in pregnant rabbits with pegvisomant at subcutaneous doses of 1, 3, and 10 mg/kg/day. There was no evidence of teratogenic effects associated with pegvisomant administration during organogenesis. At the 10-mg/kg/day dose (6 times the maximum human therapeutic dose based on body surface area), a reproducible, slight increase in post-implantation loss was observed in 8.2 Lactation **Risk Summary** Limited information from a case report in published literature reported that the level of pegvisomant in human milk was below the level of detection. There is no information available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SOMAVERT and any potential adverse effects on the breastfed child from SOMAVERT or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential Discuss the potential for unintended pregnancy with premenopausal women as the therapeutic benefits of a reduction in growth hormone (GH) levels and normalization of insulin-like growth factor 1 (IGF-1) concentration in acromegalic females treated with pegvisomant may lead to improved fertility. 8.4 Pediatric Use The safety and effectiveness of SOMAVERT in pediatric patients have not been established.



PRESCRIBING **INFORMATION**

DOWNLOAD **PRINTABLE PDF**

Discussion Checklist

Learn More

PRESCRIBING **INFORMATION PAGE 4**



8.5 Geriatric Use


8.6 Renal Impairment

10 OVERDOSAGE

In one reported incident of acute overdose with SOMAVERT during pre-marketing clinical studies, a patient self-administered 80 mg/day (2.7 times the maximum recommended maintenance dosage) for seven days. The patient experienced a slight increase in fatigue, had no other complaints, and demonstrated no significant clinical laboratory abnormalities. In cases of overdose, administration of SOMAVERT should be discontinued and not resumed until IGF-I levels return to within or above the normal range.

11 DESCRIPTION

Pegvisomant is an analog of human growth hormone (GH) of recombinant DNA origin that acts as a GH receptor antagonist. It contains 191 amino acid residues. The molecular weight of pegvisomant is 22 kDa. The molecular weight of the PEG portion of pegvisomant is approximately 5 kDa. The predominant molecular weights of pegvisomant are thus approximately 42, 47, and 52 kDa. The schematic shows the amino acid sequence of the pegvisomant protein (PEG polymers are shown attached to the 5 most probable attachment sites). Pegvisomant is synthesized by a specific strain of *Escherichia coli* bacteria that has been genetically modified by the addition of a plasmid that carries a gene for GH receptor antagonist.



Shown below are the amino acid substitutions in pegvisomant, relative to human GH.

hGH	Pegvisomant
His ₁₈	Asp ₁₈
Ala ₂₁	Asn ₂₁
Gly ₁₂₀	Lys ₁₂₀
Arg ₁₆₇	Asn ₁₆₇
Lys ₁₆₈	Ala ₁₆₈
Asp ₁₇₁	Ser ₁₇₁
Lys ₁₇₂	Arg ₁₇₂
Glu ₁₇₄	Ser ₁₇₄
lle ₁₇₉	Thr ₁₇₉

respectively, with a pH of 7.1 - 7.7.

PRESCRIBING **INFORMATION PAGE 3**

Clinical studies of SOMAVERT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

SOMAVERT was not studied in patients with renal impairment and the safety and efficacy in these patients is not known.



(Phe₁, Lys₃₈, Lys₄₁, Lys₇₀, Lys₁₁₅, Lys₁₂₀, Lys₁₄₀, Lys₁₄₅, Lys₁₅₈)

SOMAVERT (pegvisomant) for injection is a sterile, white lyophilized powder intended for subcutaneous injection after reconstitution. SOMAVERT is supplied in packages that include a single-dose prefilled syringe containing 1 mL of Sterile Water for Injection USP, that is a sterile, nonpyrogenic preparation of water for injection that contains no bacteriostat, antimicrobial agent, or added buffer, to be used as a diluent.

SOMAVERT is available in single-dose sterile vials containing 10 mg, 15 mg, 20 mg, 25 mg or 30 mg of pegvisomant. SOMAVERT 10 mg, 15 mg, and 20 mg vials also contain glycine (1.36 mg), mannitol (36 mg), sodium dihydrogen phosphate monohydrate (0.36 mg), and sodium phosphate dibasic anhydrous (1.04 mg). After reconstitution with 1 mL of Water for Injection, USP, the resulting concentration is 10 mg/mL, 15 mg/mL and 20 mg/mL,

SOMAVERT 25 mg vial also contains glycine (1.7 mg), mannitol (45 mg), sodium dihydrogen phosphate monohydrate (0.45 mg), and sodium phosphate dibasic anhydrous (1.3 mg). After reconstitution with 1 mL of Water for Injection, USP, the resulting concentration is 25 mg/mL with a pH of 7.1 - 7.7.

SOMAVERT 30 mg vial also contains glycine (2.04 mg), mannitol (54 mg), sodium dihydrogen phosphate monohydrate (0.54 mg), and sodium phosphate dibasic anhydrous (1.56 mg). After reconstitution with 1 mL of Water for Injection, USP, the resulting concentration is 30 mg/mL with a pH of 7.1 - 7.7.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of IGF-I, as well as other GH-responsive serum proteins such as free IGF-I, the acid-labile subunit of IGF-I (ALS), and insulin-like growth factor binding protein-3 (IGFBP-3).

12.2 Pharmacodynamics

Pegvisomant binds selectively to the GH receptor, and does not cross-react with 19 other cytokine receptors tested, including prolactin. Pegvisomant leads to decreased serum concentrations of IGF-I, free IGF-I, ALS, and IGFBP-3 [see Clinical Studies (14, Figure 1)].

12.3 Pharmacokinetics

Absorption: Following subcutaneous administration, peak serum pegvisomant concentrations are not generally attained until 33 to 77 hours after administration. The mean extent of absorption of a 20-mg subcutaneous dose was 57%, relative to a 10-mg intravenous dose.

Distribution: The mean apparent volume of distribution of pegvisomant is 7 L (12%) coefficient of variation), suggesting that pegvisomant does not distribute extensively into tissues. After a single subcutaneous administration, exposure (C_{max}, AUC) to pegvisomant increases disproportionately with increasing dose. Mean ± SEM serum pegvisomant concentrations after 12 weeks of therapy with daily doses of 10, 15, and 20 mg were 6600 ± 1330 ; 16,000 ± 2200 ; and 27,000 ± 3100 ng/mL, respectively. The relative bioavailability of 1×30 mg pegvisomant was compared to 2×15 mg pegvisomant in a single-dose study. The AUC_{inf} and C_{max} of pegvisomant when administered as one injection of 30 mg strength was approximately 6% and 4% greater, respectively, as compared to when administered as two injections of 15 mg strengths. *Metabolism and Elimination:* The pegvisomant molecule contains covalently bound polyethylene glycol polymers in order to reduce the clearance rate. Clearance of pegvisomant following multiple doses is lower than seen following a single-dose. The mean total body systemic clearance of pegvisomant following multiple doses is estimated to range between 36 to 28 mL/h for subcutaneous doses ranging from 10 to 20 mg/day, respectively. Clearance of pegvisomant was found to increase with body weight. Pegvisomant is eliminated from serum with a mean half-life estimates ranging from 60 to 138 hours following either single or multiple doses. Less than 1% of administered drug is recovered in the urine over 96 hours. The elimination route of pegvisomant has not been studied in humans.

Drug Interaction Studies

In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. The mechanism of this interaction is not known *[see Drug Interactions*] (7.2)].

Specific Populations

No pharmacokinetic studies have been conducted in patients with renal impairment, patients with hepatic impairment, geriatric patients, or pediatric patients and the effects of race on the pharmacokinetics of pegvisomant has not been studied. No gender effect on the pharmacokinetics of pegvisomant was found in a population pharmacokinetic analysis.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis

Pegvisomant was administered subcutaneously to rats daily for 2 years at doses of 2, 8, and 20 mg/kg (about 2, 9, and 22-fold a single 30 mg dose in humans on an AUC basis). Long term treatment with pegvisomant at 8 and 20 mg/kg caused an increase in malignant fibrous histiocytoma at injection sites in males. Injection site tumors were not seen in female rats at the same doses. The increased incidence of injection site tumors was most probably caused by irritation and the high sensitivity of the rat to repeated subcutaneous injections.

Mutagenesis

Pegvisomant did not cause genetic damage in standard *in vitro* assays (bacterial mutation, human lymphocyte chromosome aberration).

Impairment of Fertility

Fertility studies have not been conducted with pegvisomant.

14 CLINICAL STUDIES

A total of one hundred twelve patients (63 men and 49 women) with acromegaly participated in a 12-week, randomized, double-blind, multi-center study comparing placebo and SOMAVERT. The mean \pm SD age was 48 \pm 14 years, and the mean duration of acromegaly was 8±8 years. Ninety three had undergone previous pituitary surgery, of which 57 had also been treated with conventional radiation therapy. Six patients had undergone irradiation without surgery, nine had received only drug therapy, and four had received no previous therapy. At study start, the mean \pm SD time since the subjects' last surgery and/or irradiation therapy, respectively, was 6.8 ± 0.93 years (n=63) and 5.6 ± 0.57 years (n=93). Subjects were qualified for enrollment if their serum IGF-I, drawn after the required drug washout period, was ≥ 1.3 times the upper limit of the age-adjusted normal range. They were randomly assigned at the baseline visit to one of four treatment groups: placebo




PRESCRIBING INFORMATION

DOWNLOAD PRINTABLE PDF







PRESCRIBING **INFORMATION PAGE 4**

(n=32), 10 mg/day (n=26), 15 mg/day (n= 26), or 20 mg/day (n=28) of SOMAVERT subcutaneously IGF-I. The primary efficacy endpoint was IGF-I percent change in IGF-I concentrations from baseline to week 12. The three groups that received SOMAVERT showed statistically significant (p<0.01) reductions in serum levels of IGF-I compared


Table 4. Mean Percent Change from Baseline in IGF-I at Week 12 for Intent-to-Treat

	Placebo	SOMAVERT		
	n=31	10 mg/day n=26	15 mg/day n=26	20 mg/day n=28
GF-I	670 (288)	627 (251)	649 (293)	732 (205)
ange ⁻ -I (SD)	-4.0 (17)	-27 (28)	-48 (26)	-63 (21)
ius nent		-23* (-35, -11)	-44* (-56, -33)	-59* (-68, -49)

* P<0.01; n = number of patients; SD = standard deviation

There were also reductions in serum levels of free IGF-I, IGFBP-3, and ALS compared with

Figure 1. Effects of SOMAVERT on Serum Markers (Mean ± Standard Error)



Placebo (n=31)

▲ SOMAVERT 15 mg/day (n=24-26) ◆ SOMAVERT 10 mg/day (n=25-26) ◆ SOMAVERT 20 mg/day (n=27-28)

After 12 weeks of treatment, the following percentages of patients had normalized IGF-1

Figure 2. Percent of Patients Whose IGF-I Levels Normalized at Week 12





Table 5 shows the effect of treatment with SOMAVERT on ring size (standard jeweler's sizes converted to a numeric score ranging from 1 to 63), and on signs and symptoms of acromegaly. Each individual score for a sign or symptom of acromegaly (for soft-tissue swelling, arthralgia, headache, perspiration and fatigue) was based on a nine-point ordinal rating scale (0 = absent and 8 = severe and incapacitating), and the total score for signs or symptoms of acromegaly was derived from the sum of the individual scores. Mean baseline scores were as follows: ring size = 47.1; total signs and symptoms = 15.2; soft tissue swelling = 2.5; arthralgia = 3.2; headache = 2.4; perspiration = 3.3; and fatigue = 3.7.

Table 5. Mean Change from Baseline (SD) at Week 12 for Ring Size and Signs and Symptoms of Acromenaly

	nogary			
	Placebo n=30	10 mg/day n=26	15 mg/day n=24-25	20 mg/day n=26-27
Ring size	-0.1 (2.3)	-0.8 (1.6)	-1.9 (2.0)	-2.5 (3.3)
Total score for signs and symptoms of acromegaly	1.3 (6.0)	-2.5 (4.3)	-4.4 (5.9)	-4.7 (4.7)
Soft-tissue swelling	0.3 (2.3)	-0.7 (1.6)	-1.2 (2.3)	-1.3 (1.3)
Arthralgia	0.1 (1.8)	-0.3 (1.8)	-0.5 (2.5)	-0.4 (2.1)
Headache	0.1 (1.7)	-0.4 (1.6)	-0.3 (1.4)	-0.3 (2.0)
Perspiration	0.1 (1.7)	-0.6 (1.6)	-1.1 (1.3)	-1.7 (1.6)
Fatigue	0.7 (1.5)	-0.5 (1.4)	-1.3 (1.7)	-1.0 (1.6)

Serum growth hormone (GH) concentrations, as measured by research assays using antibodies that do not cross-react with pegvisomant, rose within two weeks of beginning treatment with SOMAVERT. The largest increase in GH concentration was seen in patients treated with doses of SOMAVERT 20 mg/day. This effect is presumably the result of diminished inhibition of GH secretion as IGF-I levels fall. As shown in Figure 3, when patients with acromegaly were given a loading dose of SOMAVERT followed by a fixed daily dose, the rise in GH was inversely proportional to the fall in IGF-I and generally stabilized by week 2. Serum GH concentrations remained stable in patients treated with SOMAVERT for the average of 43 weeks (range, 0-82 weeks).





In the open-label extension to the clinical study, 109 subjects (including 6 new patients) with mean treatment exposure of 42.6 weeks (range 1 day – 82 weeks), 93 (85.3%) subjects had an adverse event, 16 (14.7%) had an SAE, and 4 (3.7%) discontinued due to an AE (headaches, elevated liver function tests, pancreatic cancer, and weight gain). A total of 100 (92.6%) of the 108 subjects with available IGF-I data had a normal IGF-I concentration at any visit during the study.

16 HOW SUPPLIED/STORAGE AND HANDLING

SOMAVERT (pegvisomant) for injection is a white lyophilized powder supplied in the following strengths and package configurations:

One Day Package Configuration				
Strength	NDC	Description		
10 mg per vial	0009-7166-01	One single-dose vial with or		
15 mg per vial	0009-7168-01	 prefilled syringe containing diluent (Sterile Water for Inj 		
20 mg per vial	0009-7188-01	USP) and a separate 27 -ga		
25 mg per vial	0009-7199-01	½ inch safety needle per car		
30 mg per vial	0009-7200-01			



DOWNLOAD PRINTABLE PDF

	000	\bigcirc
Γ	200	<u>o`</u>
ŀ	150	line
-	100	ase
-	50	В Д
╞	0	fror
╞	-50	Эдс
╞	-100	hange
╞	-150	Н С Н
L	-200	G

one g 1 mL of njection, auge arton





30-Day Package Configuration				
Strength	NDC	Description		
10 mg per vial	0009-7166-30	Each outer carton contains three		
15 mg per vial	0009-7168-30	intermediate cartons, 30 prefilled syringes containing 1 mL of diluent		
20 mg per vial	0009-7188-30	(Sterile Water for Injection, USP),		
25 mg per vial	0009-7199-30	and 30 separate 27-gauge ½ inch safety needles. Each intermediate		
30 mg per vial	0009-7200-30	carton contains ten single-dose vials of Somavert.		

Storage

Prior to reconstitution

- 8°C (36°F to 46°F)

date. whichever is sooner. Do not freeze

17 PATIENT COUNSELING INFORMATION

Instructions for Use). effective use of SOMAVERT

- on the results of these tests.

- **IGF-I** suppression.

do not shake).

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

Pfizer

Manufactured by Pharmacia & Upjohn Company LLC A subsidiary of Pfizer Inc. New York, NY 10017

U.S. License No. 1216 LAB-0782-3.0

PRESCRIBING **INFORMATION PAGE 5**

• The One Day Package of SOMAVERT should be stored in a refrigerator at 2°C to

• For the 30-Day Package, remove the three intermediate cartons containing the SOMAVERT vials and store in a refrigerator at 2°C to 8°C (36°F to 46°F).

• For convenience, the One Day Package and intermediate cartons in the 30-Day Package containing the SOMAVERT vial(s), may be stored at room temperature up to 25°C (77°F) for a single period of up to 30 days.

• In the space provided on the carton, record the date when the carton was removed from the refrigerator and the discard date (30 days after removal from the refrigerator).

• Once the carton has been stored at room temperature, it should not be placed back into the refrigerator. If not used within 30 days at room temperature, the vial(s) should be discarded.

Discard the SOMAVERT vial(s) after the expiration date printed on the carton or the discard

The prefilled syringe(s) may be stored at a temperature up to 30°C (86°F) until the expiration date printed on the carton, at which point they should be discarded.

Advise the patient to read the FDA-approved patient labeling (Patient Information and

Inform patients (and/or their caregivers) of the following information to aid in the safe and

• Not to use SOMAVERT if they are allergic to SOMAVERT or anything in it.

• They will need blood testing to check IGF-I levels and liver tests before and during treatment with SOMAVERT and that the dose of SOMAVERT may be changed based

• SOMAVERT has not been studied in pregnant women and instruct them to notify their healthcare provider as soon as they are aware that they are pregnant.

• It is not known whether SOMAVERT is excreted in human milk and instruct them to notify their healthcare provider if they plan to do so.

• Pregnancy: Inform female patients that treatment with SOMAVERT may result in unintended pregnancy [see Females and Males of Reproductive Potential (8.3)].

Advise patients (and/or their caregivers) of the following adverse reactions:

• The most common reported adverse reactions are injection site reaction, elevations of liver tests, pain, nausea, and diarrhea.

• If they have liver test elevations they may need to have more frequent liver tests and/or discontinue SOMAVERT. Instruct patients to immediately discontinue therapy and contact their physician if they become jaundiced.

• GH-secreting tumors may enlarge in people with acromegaly and that these tumors need to be watched carefully and monitored by MRI imaging.

• Thickening under the skin may occur at the injection site that could lead to lumps and that switching sites may prevent or lessen this.

• If they have diabetes mellitus, they may require careful monitoring and dose reductions of insulin and/or oral hypoglycemic agents while on SOMAVERT.

• If they take opioids, they may need higher SOMAVERT doses to achieve appropriate

Inform patients (and/or their caregivers) about the storage options prior to reconstitution of the product [see How Supplied/Storage and Handling (16)].

Advise patients to follow the directions for reconstitution provided in the Instructions for Use. Include that spraying the diluent directly onto the powder may cause foaming and that shaking may induce denaturation (destruction) of the active ingredient (therefore

IMPORTANT SAFETY

INFORMATION

PATIENT INFORMATION SOMAVERT (SOM-ah-vert) (pegvisomant) for injection, for subcutaneous use

What is SOMAVERT?

SOMAVERT is a prescription medicine used to treat people who have too much growth hormone (acromegaly). SOMAVERT is used to treat people who are not able to be treated or have not already been helped by surgery or radiation.

It is not known if SOMAVERT is safe and effective in children.

Before you use SOMAVERT, tell your healthcare provider about all of your medical conditions, including if you:

- are allergic to pegvisomant or any of the ingredients in SOMAVERT. Do not take SOMAVERT if you are allergic to pegvisomant or any of the ingredients in SOMAVERT. See the end of this leaflet for a complete list of ingredients in SOMAVERT.
- have diabetes
- have or have had liver problems
- are pregnant or plan to become pregnant. It is not known if SOMAVERT will harm your unborn baby. Tell your healthcare provider if you become pregnant while using SOMAVERT.
- are breastfeeding or plan to breastfeed. It is not known if SOMAVERT passes into your breast milk. You and your health care provider should decide how you will feed your baby if you take SOMAVERT.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

SOMAVERT may affect the way other medicines work, and other medicines may affect how SOMAVERT works. Especially tell your healthcare provider if you take:

- insulin or other medicines used to treat diabetes
- narcotics (opioid medicines). Your healthcare provider may change your dose of SOMAVERT if you take opioids.

If you are not sure, ask your healthcare provider or pharmacist whether you take these medicines.

How should I use SOMAVERT?

- Read the **Instructions for Use** at the end of this Patient Information for information about the right way to use SOMAVERT.
- Your healthcare provider should do blood tests to check your liver and insulin-like growth factor-I (IGF-I) levels before you start and while you use SOMAVERT. Your healthcare provider may need to change your dose of SOMAVERT.
- SOMAVERT is given 1 time each day as an injection under your skin (subcutaneous). Some people may need to give 2 injections for their dose each day. Your healthcare provider will tell you if you need to give 2 injections for your dose.
- Your first injection of SOMAVERT should be given by your healthcare provider.
- Your healthcare provider will teach you or your caregiver how to use SOMAVERT.
- If you use too much SOMAVERT, call your healthcare provider right away.
- If you miss a dose of SOMAVERT, just take the next dose at the regular time. Do **not** take 2 doses at the same time. If you are not sure about your dosing, ask your healthcare provider.

PRESCRIBING INFORMATION

DOWNLOAD **PRINTABLE PDF**



۱		
L		





What are the possi
SOMAVERT may ca
• changes in your
change your dos
 liver problems. healthcare provide
problems:
 yellowing of yo dark amber oo
 dark, amber-co feeling very tire
 nausea and vol
 skin thickening
(lipohypertrophyallergic reaction
any of the follow
 swelling of you wheezing or t
 skin rash, red
The most common
 pain infection
 nausea
• flu syndrome
These are not all of
information, ask yo
Tell your healthcare
that does not go aw
Call your doctor for effects to FDA at 1-
How should I store
Before you mix
 Store SOMAV For convenie
in the 30-Day
in the 30-Day stored at roo
in the 30-Day stored at roo up to 30 days
in the 30-Day stored at roo up to 30 days o In the cartor
in the 30-Day stored at room up to 30 days o In the cartor (30 day
in the 30-Day stored at room up to 30 days o In the cartor (30 day o Once
in the 30-Day stored at room up to 30 days o In the cartor (30 day o Once should within
in the 30-Day stored at room up to 30 days o In the cartor (30 day o Once should within throw
in the 30-Day stored at room up to 30 days o In the cartor (30 day o Once should within
in the 30-Day stored at room up to 30 days o In the cartor (30 da o Once should within throw • Throw away the the carton or the • The prefilled syr
in the 30-Day stored at root up to 30 days o In the cartor (30 da o Once should within throw • Throw away the the carton or the the prefilled syn until the expiration
 in the 30-Day stored at room up to 30 days In the cartor (30 day) Once should within throw Throw away the the carton or the the carton or the the carton or the be thrown away.
in the 30-Day stored at root up to 30 days o In the cartor (30 da o Once should within throw • Throw away the the carton or the the prefilled syn until the expiration
 in the 30-Day stored at root up to 30 days In the cartor (30 da Once should within throw Throw away the the carton or the the carton or the the carton or the the carton or the the thrown away. The prefilled syr until the expiration be thrown away. Do not freeze SC Read the INSTR After you mix the syn and the the syn amagement of the s
 in the 30-Day stored at room up to 30 days In the carton (30 da) Once should within throw Throw away the the carton or the be thrown away. Do not freeze SC Read the INSTR After you mix th o Keep the mix
 in the 30-Day stored at room up to 30 days In the cartor (30 day) Once should within throw Throw away the the carton or the be thrown away. Do not freeze SC Read the INSTR After you mix th o Keep the mix 77°F (15°C the second secon
 in the 30-Day stored at room up to 30 days In the cartor (30 day) Once should within throw Throw away the the carton or the the carton or the the carton or the the carton or the be thrown away. Do not freeze SC Read the INSTR After you mix th o Keep the mix 77°F (15°C the carton or the the the the the the the carton or the the the the the the the the the the
 in the 30-Day stored at room up to 30 days In the cartor (30 day) Once should within throw Throw away the the carton or the the the carton or the the the the the the the the the the
 in the 30-Day stored at room up to 30 days In the cartor (30 da) Once should within throw Throw away the the carton or the the carton or the the carton or the the carton or the the carton away. Do not freeze SC Read the INSTR After you mix th Keep the mix 77°F (15°C the the carton or the the the carton or the the the the the the the the the the
 in the 30-Day stored at room up to 30 days In the carton (30 day) Once should within throw Throw away the the carton or the the carton or the the carton or the the carton or the be thrown away. Do not freeze SC Read the INSTR After you mix th Keep the mix 77°F (15°C the second se
 in the 30-Day stored at room up to 30 days In the cartor (30 da) Once should within throw Throw away the the carton or the the carton or the the carton or the the carton or the the carton away. Do not freeze SC Read the INSTR After you mix th Keep the mix 77°F (15°C the the carton or the the the carton or the the the the the the the the the the

PRESCRIBING **INFORMATION PAGE 6**

ossible side effects of SOMAVERT?

v cause serious side effects, including:

our blood sugar level. Your healthcare provider may dose of diabetes medicine while you take SOMAVERT. **ns.** Stop injecting SOMAVERT right away and call your ovider if you have any of the following symptoms of liver

your eyes (jaundice)

- pain in your stomach (abdomen)
- -colored urine
- generalized swelling
- vomitina
- tired (fatigue or exhaustion) o bruising easily

ng at your injection site that could lead to lumps phy)

tions. Call your healthcare provider right away if you have lowing symptoms of a serious allergic reaction:

- your face, tongue, lips, or throat o severe itching • dizziness or fainting
- or trouble breathing
- redness, or swelling

ion side effects of SOMAVERT include:

- injection site reaction
- diarrhea
- abnormal liver tests. If your liver test results are too high, you may have to have more frequent liver tests
- I of the possible side effects of SOMAVERT. For more your healthcare provider or pharmacist.
- are provider if you have any side effect that bothers you or away.
- for medical advice about side effects. You may report side 1-800-FDA-1088.

ore SOMAVERT?

nix the SOMAVERT powder and the liquid:

AVERT in a refrigerator at 36°F to 46°F (2°C to 8°C).

nience, the One Day Package and intermediate cartons -Day Package containing the SOMAVERT vial(s), may be room temperature up to 77°F (25°C) for a single period of ays.

the space provided on the carton, record the date when the ton was removed from the refrigerator and the discard date) days after removal from the refrigerator).

ce the carton has been stored at room temperature, it ould not be placed back into the refrigerator. If not used thin 30 days at room temperature, the vial(s) should be own away.

the SOMAVERT vial(s) after the expiration date printed on the discard date, whichever is sooner.

syringe(s) maybe stored at temperature up to 86°F (30°C) ration date printed on the carton. After that time, they should

SOMAVERT.

STRUCTIONS FOR USE for the right way to mix SOMAVERT. the SOMAVERT powder and liquid:

mixed SOMAVERT at room temperature between 59°F to °C to 25°C).

AVERT inside the vial or the syringe until you are ready to

use the mixed SOMAVERT immediately after you mix it. e not used the mixed SOMAVERT immediately, throw it away. and all medicines out of the reach of children.

General information about the safe and effective use of SOMAVERT.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SOMAVERT for a condition for which it was not prescribed. Do not give SOMAVERT to other people, even if they have the same symptoms that you have. It may harm them. This Patient Information summarizes the most important information about SOMAVERT. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about SOMAVERT that is written for health professionals.

What are the ingredients in SOMAVERT?

Active ingredient: pegvisomant, including polyethylene glycol **Inactive** ingredients: glycine, mannitol, sodium dihydrogen phosphate monohydrate, and sodium phosphate dibasic anhydrous.

Pfizer

Manufactured by Pharmacia & Upjohn Company LLC A subsidiary of Pfizer Inc. New York, NY 10017

U.S. License No. 1216 LAB-0783-3.0 For more information, go to www.SOMAVERT.com or call 1-800-645-1280.

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 8/2021



PRESCRIBING INFORMATION

DOWNLOAD **PRINTABLE PDF**





- you inject it for the first time.

- needles)
- of up to 30 days.
- thrown away.
- they should be thrown away.
- Do not freeze SOMAVERT.

Important:

- infection from them.

Step 1. Things you need

- A prefilled syringe.
- A safety needle
- You will also need:
- A cotton ball.
- An alcohol swab.
- instructions.

PRESCRIBING **INFORMATION PAGE 7**

INSTRUCTIONS FOR USE SOMAVERT® (SOM-ah-vert) (pegvisomant)

for injection, for subcutaneous use

Read these Instructions for Use before you start using SOMAVERT and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment. Your healthcare provider should show you or a caregiver how to inject SOMAVERT the right way before

SOMAVERT is available in two types of packaging:

• One Day Package (containing one single-dose vial of SOMAVERT powder, a prefilled syringe, and a safety needle)

• 30-Day Package (containing three intermediate cartons of 10 singledose vials of SOMAVERT powder, 30 prefilled syringes, and 30 safety

• Before you mix the SOMAVERT powder and the liquid:

• Store SOMAVERT in a refrigerator at 36 °F to 46 °F (2 °C to 8 °C).

• For convenience, the One Day Package and intermediate cartons in the 30-Day Package containing the SOMAVERT vial(s), may be stored at room temperature up to 77°F (25°C) for a single period

• In the space provided on the carton, record the date when the carton was removed from the refrigerator and the discard date (30 days after removal from the refrigerator).

• Once the carton has been stored at room temperature, it should not be placed back into the refrigerator. If not used within 30 days at room temperature, the vial(s) should be

• Throw away the SOMAVERT vial(s) after the expiration date printed on the carton or the discard date, whichever is sooner.

• The prefilled syringe(s) maybe stored at temperature up to 86° (30°C) until the expiration date printed on the carton. After that time,


• Do not share your SOMAVERT syringes or needles with other people. You may give other people a serious infection, or get an

• SOMAVERT comes in a vial as a white block of powder. You must mix SOMAVERT with a liquid (diluent) before you can use it. The liquid comes in a single-dose prefilled syringe labeled 'Sterile Water for Injection'. **Do not** use any other liquid to mix with SOMAVERT.

• You must use the mixed SOMAVERT immediately after you mix it. If you have not used the mixed SOMAVERT immediately, throw it away.

A vial of SOMAVERT powder.

• A sharps disposal container. See "Dispose" at the end of these




Step 2. Getting ready

Before you start:

- Only mix SOMAVERT and the liquid when you are ready to inject your dose.
- SOMAVERT One Day Package: If refrigerated, remove the package and allow it to come to room temperature in a safe place for at least **10 minutes** before you need to use it.
- SOMAVERT 30-Day Package: If refrigerated, remove a single vial from the intermediate carton and allow it to come to room temperature in a safe place for at least **10 minutes** before you need to use it.
- **Do not** heat the vial or syringe by using a heat source such as hot water or microwave. Let it warm up on its own.
- Wash your hands with soap and water, and dry completely.
- Peel open the packaging of the syringe and safety needle to make it easier to pick up each item as you prepare for your injection.
- **Do not** use the syringe or vial if:
 - they are damaged or faulty
 - the expiration date has passed
 - it has been frozen, even if it has now that (syringe only)

Step 3. Choose injection area



- Choose a different location within an area for each injection.
- Avoid bony areas or areas that are bruised, red, sore or hard, or areas that have scars or skin conditions.
- Clean the injection area with the alcohol swab as instructed by your healthcare provider.
- Allow the injection area to dry.

IMPORTANT SAFETY INFORMATION

PRESCRIBING **INFORMATION**

DOWNLOAD **PRINTABLE PDF**

Discussion Checklist





Step 4. Remove
 Remove the Throw the calculation: Do Step 5. Remove s
 Snap off the take more effective take
• Push down far as it will

PRESCRIBING **INFORMATION PAGE 8**

vial cap



e cap from the vial.

cap away. It is not needed again. **not** let anything touch the vial stopper.

syringe cap



- e syringe cap leaving the syringe collar in place. It may effort to snap off than you might expect.
- syringe cap away. It is not needed again.
- ringe upright to avoid leakage.
- **not** let the end of the syringe touch anything when the) is off.

afety needle




and twist the safety needle firmly onto the syringe as lgo.

Step 7. Remove needle cover




- Fold the needle guard out of the way of the needle cover.
- Carefully pull the needle cover straight off.
- Throw the needle cover away. It is not needed again.
 Caution: Do not let the needle touch anything.

Step 8. Insert needle



- Push the needle through the center of vial stopper, as shown.
- Support the syringe while the needle is in the vial stopper to prevent bending the needle.

Step 9. Add liquid



- Tilt both the vial and syringe at an angle, as shown.
- Push the plunger rod down slowly until all the liquid has emptied into the vial.
- **Caution: Do not** squirt the liquid directly onto the powder. This creates foam. Foam makes the medicine unusable.
- Do not withdraw the needle yet.



PRESCRIBING INFORMATION

DOWNLOAD PRINTABLE PDF


Discussion Checklist





Step	10. Swirl vi
e • • Step	Support bo Gently and motion on a Continue sy Note: This Do no 11. Check r
• • Step	Keeping the It must be o Do not use o the o the o the o the If you have www.SOMA 12. Reposit
•	Turn the via Pull the nee the liquid. T Check that moved, the that all air is

PRESCRIBING **INFORMATION PAGE 9**



oth the syringe and vial in 1 hand, as shown. d **slowly** swirl the liquid, sliding the vial in a circular a flat surface.

swirling the liquid until all the powder has fully dissolved. s may take up to 5 minutes. **not shake.**


medicine



ne needle in the vial, look carefully at the medicine. clear and free of particles.


- e medicine is cloudy or hazy e medicine has any color at all ere are any particles or foam in the vial
- e any doubts about your medication go to AVERT.com or call 1-800-645-1280.

ition needle




ial so that you can see the stopper gap, as shown. eedle down so that the needle tip is at the lowest point in This will help you to draw off as much liquid as possible. It the plunger rod has not moved. If the plunger rod has not push it back all the way into the syringe. This ensures is removed from the syringe before you draw off the dose.

Step 13. Draw off dose




- Slowly pull back the plunger rod to withdraw as much medicine as possible from the vial. **Note:** If you see air in the syringe, tap the barrel to float the bubbles to the top, and then gently push the bubbles out into the vial.
- Pull the needle out of the vial.

Step 14. Insert needle



- Gently pinch the skin at the site of injection.
- Insert the needle to its full depth into the pinched skin.

Step 15. Inject medicine



- Push the plunger rod down slowly until the barrel is empty. **Note:** Make sure you keep the needle in at full depth.
- Release the pinched skin and pull the needle straight out.



PRESCRIBING INFORMATION

DOWNLOAD PRINTABLE PDF

Discussion Checklist





Step 16. Make no
 Fold the nee Gently apply in place. Note: You w Step 17. Dispose
 Put your us right away a Do not throw Note: If you please refer hand side of Step 18. After inj
 If necessary injection are Do not rub to

PRESCRIBING **INFORMATION PAGE 10**

needle safe



edle guard over the needle.

ly pressure using a hard surface to lock the needle guard

will hear a click when the needle guard has been locked.



sed syringes in a FDA cleared sharps disposal container after use.

ow away (dispose of) syringes in your household trash. u do not have a FDA cleared sharps disposal container, r to the safe syringe disposal information on the right of this leaflet.

ijection



ry, use a clean cotton ball and press lightly on the ea.

the area.

QUESTIONS AND ANSWERS

What should I do if anything has accidentally touched the vial stopper?

• Clean the vial stopper with a fresh alcohol wipe, and leave it to dry completely. If you are unable to clean the stopper, do not use the vial.

What should I do with the syringe if it has been dropped?

• Do not use it even if it looks undamaged. Dispose of the syringe in the same way as a used syringe. You will need a replacement syringe.

How many times can I safely insert the needle into the vial stopper?

• Only 1 time. Withdrawing and reinserting greatly increases the risk of needle damage, and will blunt the needle. This can cause discomfort and increases risk of skin damage and infection. There is also a risk you may lose some of the medicine.


Is it okay to shake the vial if the powder is not dissolving?

• No. Never shake the vial. Shaking can destroy the medicine and create foam. The powder may take a few minutes to dissolve fully, so continue swirling the vial gently until the liquid is completely clear.

How can I tell if there is any foam in the vial?

• Foam looks like a mass of small bubbles that float as a layer to the top of the liquid. Do not inject SOMAVERT if it has foamed.





Tiny air bubbles are acceptable

How can I prevent the medicine from foaming?

• Press the plunger very slowly so that the liquid gently runs down the inside of the vial. Do not spray the liquid directly onto the powder, because this creates foam. This will also reduce the swirling time and allow more of the medicine to be drawn off.

I can see some air in the syringe. Is this okay?

• Tiny air bubbles in the liquid are normal and are safe to inject. However, it is possible to accidently draw air into the syringe, which should be removed before injecting. Bubbles or air gaps that float to the top of the liquid should be pushed back out into the vial.

Why can I not get all of the medicine out of the vial?

• The shape of the vial means that a very small amount of the medicine will be left behind in the vial. This is normal. To ensure that only a trace of medicine remains, make sure the needle tip is as low as it can be in the vial when drawing off your dose.

What should I do if I have any doubts about my medicine?

• For more information, go to www.SOMAVERT.com or call 1-800-645-1280.

PRESCRIBING INFORMATION

DOWNLOAD **PRINTABLE PDF**

A layer of foam is **not** acceptable





Safe syringe disposal information

If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

Administration.

Pfizer

Manufactured by Pharmacia & Upjohn Company LLC A subsidiary of Pfizer Inc. New York, NY 10017

U.S. License No. 1216 LAB-0784-2.0 Revised: August 2021

PRESCRIBING **INFORMATION PAGE 11**

 \leftarrow

o made of heavy-duty plastic,

o can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

o upright and stable during use, leak-resistant, and

o properly labeled to warn of hazardous waste inside the container.

When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.


For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal

This Instructions for Use has been approved by the U.S. Food and Drug



PRESCRIBING INFORMATION

DOWNLOAD PRINTABLE PDF



HOME